ArticleNutrition & diabetes2026
From adipokine to integrator: longitudinal galectin-1 changes mirror glycemic, hepatic, renal, and lipid remodeling after bariatric surgery.
Article in Nutrition & diabetes, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundCirculating galectin-1 levels increase with adiposity, and experimental data implicate this adipokine in the development of metabolic dysfunction. However, its longitudinal trajectory and organ-specific associations during weight loss remain poorly defined.
methodsIn this prospective study, we enrolled 117 adults with severe obesity, with a mean body mass index (BMI) 40.3 ± 5.3 kg/m², undergoing sleeve gastrectomy. Circulating galectin-1 levels and comprehensive metabolic profiles were assessed preoperatively and one year after surgery.
resultsParticipants achieved a mean total weight loss of 32.2 ± 7.8%, accompanied by significant improvements in blood pressure, glycemic control, liver enzymes, and lipid profiles. Baseline galectin-1 concentrations did not differ between participants with and without type 2 diabetes and were not associated with diabetes remission at one year. Galectin-1 levels significantly decreased from 13.2 ± 5.8 to 11.0 ± 6.5 pg/mL (p < 0.001). The percentage reduction in galectin-1 was significantly correlated with improvements in aspartate aminotransferase (AST), alanine transaminase (ALT), creatinine, total cholesterol, and low-density lipoprotein (LDL) cholesterol, but not with glycemic indices. In multivariable stepwise regression, baseline galectin-1 was independently associated with BMI, creatinine, and estimated glomerular filtration rate (eGFR). One year postoperatively, galectin-1 remained independently associated with glycated hemoglobin (A1c), quantitative insulin sensitivity check index (QUICKI), AST, ALT, creatinine, and high-density lipoprotein (HDL) cholesterol.
conclusionsGalectin-1 levels declined after weight loss and exhibited distinct associations with multiple metabolic systems. These results position galectin-1 as a potential integrative biomarker that mirrors glycemic, hepatic, renal, and lipid remodeling in response to bariatric surgery.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.